At a glance
ClinicalIndex Comparison RecordPhase 4Completed· 20 enrolled
Drug / intervention
Calcium hydroxylapatitedrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
An Open-label, Prospective, Postmarket Study to Assess Altering First Impressions and Self-esteem Following Radiesse® Injections.
In Brief
A Phase 4 clinical trial evaluating Calcium hydroxylapatite for Malar Deficiency. Completed, enrolled 20 participants across 1 site.
Detailed Summary
The purpose of this study is to determine if Radiesse injections to the cheeks result in an altered and improved first impression and self esteem.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsMalar Deficiency
CountriesUnited States
CollaboratorsMerz Aesthetics Inc.
Timeline
Phase 4CompletedFinished
2011201220132014201520162017201820192020202120222023202420252026
Enrollment StartAug 2010
First PostedOct 2010
Primary CompletionAug 2011
Study CompletionOct 2011
TodayJul 2026
First PostedOct 21, 2010
Enrollment StartAug 1, 2010
Primary CompletionAug 1, 2011
Study CompletionOct 1, 2011
TodayJul 2, 2026
Enrollment to primary: 1 yearPosted 15.7 years ago
Interventions
Calcium hydroxylapatitedrug
Subjects will be treated to full correction at visit 1 and, if needed, a touch-up injection at 2 weeks.